The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

The FDA throws out the company’s second attempt at an accelerated approval.

While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.

The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?

After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.

Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.